VTE, which is a combination of pulmonary embolism (PE) and deep venous thrombosis (DVT), is a serious, common clinical problem. Most hospitalized patients have at least one VTE risk factor, a reason for many hospitals to routinely administer blood thinners to patients although these medications...
Tasocitinib (CP-690,550) has been found to reduce the signs and symptoms of rheumatoid arthritis considerably, as well as significantly improving physical function according to a Phase 3 clinical trial, ORAL Solo (1045), says Pfizer. Tasocitinib, used as a monotherapy - on its own - is an oral...